Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 18, 2007, Pages 4351-4373

  Potashman, Michele H ^a   Bready, James ^a   Coxon, Angela ^a   Demelfi Jr , Thomas M ^a   DiPietro, Lucian ^a   Doerr, Nicholas ^a   Elbaum, Daniel ^a   Estrada, Juan ^a   Gallant, Paul ^a   Germain, Julie ^a   Gu, Yan ^a   Harmange, Jean Christophe ^a   Kaufman, Stephen A ^a   Kendall, Rick ^a   Kim, Joseph L ^a   Kumar, Gondi N ^a   Long, Alexander M ^a   Neervannan, Seshadri ^a   Patel, Vinod F ^a   Polverino, Anthony ^a   Rose, Paul ^a   Van Der Plas, Simon ^a   Whittington, Douglas ^a   Zanon, Roger ^a   Zhao, Huilin ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[2 [[4 CHLORO 3 [[(1 METHYL 2 PYRROLIDINYL)METHYL]OXY]PHENYL]AMINO] 1,3 BENZOXAZOL 5 YL]OXY] N METHYL 2 PYRIDINECARBOXAMIDE; 5 [[6,7 BIS(METHOXY) 4 QUINOLINYL]OXY] N [4 CHLORO 3 [(4 METHYL 1 PIPERAZINYL)METHYL]PHENYL] 1,3 BENZOXAZOL 2 AMINE; [4 CHLORO 3 (1 METHYLPYRROLIDIN 2 YLMETHOXY)PHENYL][5 (6,7 DIMETHOXYQUINAZOLIN 4 YLOXY)BENZOXAZOL 2 YL]AMINE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; MATRIGEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MOLECULAR MODEL; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOXAZOLES; BIOLOGICAL AVAILABILITY; CAPILLARY PERMEABILITY; CELL PROLIFERATION; CELLS, CULTURED; CORNEA; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34548475073     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070034i     Document Type: Article

References (33)

1. Ferrara, N. Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implications. Semin. Oncol. 2002, 29 (6 Suppl. 16), 10-14.
2. Walsh, D. A. Angiogenesis and Arthritis. Rheumatology 1999, 38, 103-112.
3. Ferrara, N.; Alitalo, K. Clinical Applications of Angiogenic Growth Factors and their Inhibitors. Nat. Med. 1999, 5, 1359-1364.
4. Folkman, J. Role of Angiogenesis in Tumor Growth and Metastasis. Semin. Oncol. 2002, 29 (6 Suppl. 16), 15-18.
5. Ferrara, N. Role of Vascular Endothelial Growth Factor in the Regulation of Angiogenesis. Kidney Int. 1999, 56, 794-814.
6. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic Inhibitors: A New Therapeutic Strategy in Oncology. Nat. Clin. Prac. Oncol. 2005, 2, 562-577.
7. Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W. Discovery and Development of Bevacizumab, an anti-VEGF Antibody for Treating Cancer. Nat. Rev. Drug Discovery 2004, 3, 391-400.
8. Sakamoto, K. M. SU-11248 SUGEN. Curr. Opin. Invest. Drugs 2004, 5, 1329-1339.
9. Ahman, T.; Eisen, T. Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma. Clin. Cancer Res. 2004, 10 (Suppl.), 6388s-6392s.
10. (a) PTK-787: Thomas, A. L.; Morgan, B.; Dreves, J.; Unger, C.; Wiedenmann, B.; Vanhoefer, U.; Laurent, D.; Dugan, M; Steward, W. P. Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003, 30 (Suppl 6), 32-38.
11. (b) ZD-6474: Ryan, A. J.; Wedge, S. R. ZD6474-A Novel Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. Br. J. Cancer 2005, 92 (Suppl 1), S6-S13.
12. (c) CEP-7055: Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbet, J.-M.; Bono, F.; Scheffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. Cancer Res. 2003, 63, 5978-5991.
13. (d) CP-547632: Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological Characterization of CP-547,632, a novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy. Cancer Res. 2003, 63, 7301-7309.
14. (e) Motesanib: Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts. Cancer Res. 2006, 66, 8715-8721.
15. 50 of 90 nM. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64, 7099-7109.
16. Patel, V. The Discovery and Properties of AMG 706: A Multikinase Angiogenesis Inhibitor in Clinical Trials. Presented at ACS ProSpectives, Cambridge, MA, May 2006.
17. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science 2000, 289, 1938-1942.
18. Other receptor tyrosine kinases have been shown to adopt this conformation also. (a) Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B.-C.; Wilson, K. P. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase. J. Biol. Chem. 2004, 279, 31655-31663.
19. (b) Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site. Nat. Struct. Biol. 2002, 9, 268-272.
20. (c) Liu, Y.; Gray, N. S. Rational Design of Inhibitors that Bind to Inactive Conformations. Nat. Chem. Biol. 2006, 2, 358-364.
21. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties that Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615-2623.
22. Compound 3 was claimed as a raf inhibitor in the following Chiron patent application: Substituted Benzoxazoles and Use Thereof as Raf Kinase Inhibitors. WO2003082272, 2003.
23. For most of the substrates, the reactions were carried out neat. However, in the preparation of compound 52d (containing the pyrrolopyrimidine moiety), use of triethylamine and trifluroacetic acid (1:1 mixture) as the solvent was required. Even under these conditions, the product was isolated in a poor 14% yield.
24. The following reference provides support for CH-O hydrogen-bonds in protein-ligand interactions: Pierce, A. C.; Sandrettio, K. L.; Bemis, G. W. Kinase Inhibitors and the Case for CH-O Hydrogen Bonds in Protein-Ligand Binding. Proteins: Struct., Funct., Genet. 2002, 49, 567-576.
25. Miles, A. A.; Miles, E. M. Vascular Reactions to Histamine, Histamine-Liberator and Leucotaxin in the Skin of Guinea Pigs. J. Physiol. 1952, 118, 228-257.
26. 50 of 16.3 mg/kg (AUC = 17.03 μM·h).
27. Bankston, D.; Dumas, J.; Natero, R.; Riedl, B.; Monahan, M.-K.; Sibley, R. A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer. Org. Proc. Res. Dev. 2002, 6, 777-781.
28. Schneller, S. W.; Luo, J.-K. Synthesis of 4-Amino-1H-Pyrrolo[2,3- b]pyridine (1,7-Dideazaadenine) and 1H-Pyrrolo[2,3-b] pyridine-4-ol (1,7-Dideazahypoxanthine). J. Org. Chem. 1980, 45, 4045-4048.
29. 1-Selective Adrenoceptor Antagonists. 2. 4-Ether-Linked Phenoxypropanolamines. J. Med. Chem. 1983, 26, 1570-1576.
30. Meigh, J.-P.; Alvarez, M.; Joule, J. A. Cyclic Ureas as ortho-Directing Substituents. J. Chem. Soc., Perkin Trans. 1 2001, 2012-2021.
31. Kubo, K.; Ohyama, S.-i.; Shimizu, T.; Takami, A.; Murooka, H.; Nishitoba, T.; Kato, S.; Yagi, M.; Kobayashi, T.; Iinuma, N.; Isoe, T.; Nakamura, K.; Iijima, H.; Osawa, T.; Izawa, T. Synthesis and Structure-Activity Relationship for New Series of 4-Phenoxyquinoline Derivatives as Specific Inhibitors of Platelet-Derived Growth Factor Tyrosine Kinase. Bioorg. Med. Chem. 2003, 11, 5117-5133.
32. Diehl, K.-H.; Hull, R.; Morton D.; Pfister, R.; Rabemampianina, Y.; Smith, D.; Vidal, J. M.; van de Vorstenbosch, C. A Good Practice to Guide the Administration of Substances and Removal of Blood, Including Routes and Volumes. J. Appl. Toxicol. 2001, 21, 15-23.
33. Coxon, A.; Bolon, B.; Estrada, J.; Kaufman, S.; Scully, S.; Rattan, A.; Duryea, D.; Hu, Y.-L.; Rex, K.; Pacheco, E.; Van, G.; Zack, D.; Feige, U. Inhibition of Interleukin-1 but Not Tumor Necrosis Factor Suppresses Neovascularization in Rat Models of Corneal Angiogenesis and Adjuvant Arthritis. Arthritis Rheum. 2002, 46, 2604-2612.